Cellares, an Integrated Development and Manufacturing Organization (IDMO), has partnered with ProTgen to automate the manufacturing and quality control processes for ProT-096, a personalized progenitor T-cell therapy targeting patients with refractory leukemia and other hematologic malignancies. This collaboration leverages Cellares’ advanced Cell Shuttle and Cell Q platforms, which streamline production while providing essential regulatory support for Investigational New Drug (IND) submission.
Fabian Gerlinghaus, CEO of Cellares, emphasized the pressing need for innovation in cell therapy, particularly in addressing the manufacturing complexities that hinder progress in treating hematologic malignancies. By automating these processes, Cellares aims to enhance the speed and reliability of ProTgen’s clinical development efforts.
ProT-096 requires precision manufacturing to ensure reproducibility and cost efficiency, critical for supporting clinical trials. The integration of Cellares’ automated solutions promises to meet these demands, thereby expanding the capabilities of both companies in the evolving landscape of CAR T-cell therapies and hematopoietic stem cell programs.
ProTgen’s targeted Notch activator platform aims to rebuild immune systems compromised by cancer treatments, representing a significant advancement in immune reconstitution strategies. This partnership not only enhances ProTgen’s manufacturing capabilities but also positions both companies to better address the unmet needs of patients facing severe immune challenges.
Start your 7-day trial and see what the database can do →
